JB Chemicals & Pharma shares rise 3% after robust Q1 result, net profit jumps 25% YoY

In a press release issued after market hours on Thursday, JB Pharma said that the company recorded revenue of ₹1,004 crore in Q1FY25, registering a 12% growth from ₹896 crore in Q1FY24.

Its operating EBITDA (earnings before interest, tax, depreciation and amortisation) improved 20% to ₹292 crore during the quarter as compared to ₹243 crore a year ago.

Profit after tax (PAT) jumped 25% to ₹177 crore in Q1FY25 compared to ₹142 crore in Q1FY24.

Commenting on the earnings, JB Pharma CEO Nikhil Chopra said, “We have reached a new milestone of ₹1,000 crore in quarterly sales for the first time during any quarter, with improvement across all parameters — revenue, gross profit, operating profit and operating profit margin. Strong performance in the domestic business has continued, with each of the big brand franchises witnessing market-beating growth.”

He added, “We expect the international business, including CDMO (contract development and manufacturing organisation), to pick up in the second half of the financial year.”

While the company’s domestic formulations business recorded revenue growth of 22% year-on-year to ₹595 crore in Q1FY25, the international business revenue remained flat at ₹409 crore. JB Pharma said that the overseas revenue was impacted by muted CDMO business due to the seasonality factor and strategic choices made in international business, especially in South Africa.

On Friday, JB Pharma shares gained as much as 2.6% to hit an intraday high of ₹1,999 apiece on the NSE. However, the stock later lost momentum to close at ₹1,930 apiece, down 0.28%, on the NSE by 11:58 am.